Catalent (CTLT) Competitors

Genmab A/S (NASDAQ:GMAB) and Catalent (NYSE:CTLT) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability.

Does the MarketBeat Community prefer GMAB or CTLT?

Catalent received 495 more outperform votes than Genmab A/S when rated by MarketBeat users. However, 61.18% of users gave Genmab A/S an outperform vote while only 59.10% of users gave Catalent an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 145 61.18%	Underperform Votes 92 38.82%
Catalent	Outperform Votes 640 59.10%	Underperform Votes 443 40.90%

Is GMAB or CTLT more profitable?

Genmab A/S has a net margin of 30.74% compared to Genmab A/S's net margin of -26.61%. Catalent's return on equity of 18.90% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	30.74%	18.90%	16.83%
Catalent	-26.61%	-2.73%	-1.06%

Do analysts prefer GMAB or CTLT?

Genmab A/S currently has a consensus target price of $49.25, indicating a potential upside of 77.35%. Catalent has a consensus target price of $53.14, indicating a potential downside of 5.77%. Given Catalent's stronger consensus rating and higher probable upside, equities research analysts plainly believe Genmab A/S is more favorable than Catalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	3 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.38
Catalent	1 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Do insiders and institutionals hold more shares of GMAB or CTLT?

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 0.3% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, GMAB or CTLT?

Genmab A/S has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Which has preferable earnings and valuation, GMAB or CTLT?

Genmab A/S has higher earnings, but lower revenue than Catalent. Catalent is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$2.39B	7.68	$631.91M	$1.20	23.14
Catalent	$4.28B	2.39	-$256M	-$6.10	-9.24

Does the media refer more to GMAB or CTLT?

In the previous week, Genmab A/S had 5 more articles in the media than Catalent. MarketBeat recorded 14 mentions for Genmab A/S and 9 mentions for Catalent. Genmab A/S's average media sentiment score of 1.23 beat Catalent's score of 0.70 indicating that Catalent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalent	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Catalent on 14 of the 18 factors compared between the two stocks.